Radtke H W, Rege A B, LaMarche M B, Bartos D, Bartos F, Campbell R A, Fisher J W
J Clin Invest. 1981 Jun;67(6):1623-9. doi: 10.1172/jci110197.
Fetal mouse liver and normal human bone marrow cell cultures were used for studies on the inhibition of erythroid colony formation (CFU-E) by sera from anemic patients with end-stage renal failure and the polyamine spermine. Sera from each of eight predialysis uremic anemic patients with end-stage renal failure produced a significant (P < 0.001) inhibition of erythroid colony formation in the fetal mouse liver cell cultures when compared to sera from normal human volunteers. In vivo or in vitro dialysis of the uremic sera with a 3,500-dalton exclusion limit membrane removed the inhibitor from uremic sera. The uremic serum dialysate provided by the membrane fractionation was significantly inhibitory in the erythroid cell cultures. When this dialysate was applied to gel filtration chromatography (Bio-Gel P-2) the inhibitor was found to be in the same molecular weight range as [(14)C]spermine. The polyamine spermine produced a dose-related inhibition of erythroid colony formation (CFU-E) in fetal mouse liver and normal human bone marrow cultures. Thus, the following evidence is provided that the in vitro inhibitor of erythropoiesis found in chronic renal failure patients' sera is identical with the polyamine spermine: (a) the inhibitor and radiolabeled spermine appeared in identical Bio-Gel P-2 effluent fractions; (b) when spermine was added to normal human sera at concentrations reported in sera of uremic patients, and studied in both the fetal mouse liver cell culture and normal human bone marrow cultures, a dose-related inhibition of erythroid colony (CFU-E) formation was noted; and (c) the inhibitory effects of crude uremic serum, uremic serum dialysate, and fractions of uremic serum dialysate from a Bio-Gel column, on erythroid colony formation were completely abolished by the addition of a specific rabbit antiserum to spermine.
胎儿小鼠肝脏和正常人骨髓细胞培养物被用于研究终末期肾衰竭贫血患者的血清以及多胺精胺对红系集落形成(CFU-E)的抑制作用。与正常人类志愿者的血清相比,八名终末期肾衰竭透析前尿毒症贫血患者的血清均在胎儿小鼠肝细胞培养物中对红系集落形成产生了显著(P < 0.001)抑制作用。用截留分子量为3500道尔顿的膜对尿毒症血清进行体内或体外透析,可去除尿毒症血清中的抑制剂。经膜分级分离得到的尿毒症血清透析液在红系细胞培养中具有显著抑制作用。当将该透析液应用于凝胶过滤色谱(Bio-Gel P-2)时,发现抑制剂的分子量范围与[¹⁴C]精胺相同。多胺精胺在胎儿小鼠肝脏和正常人骨髓培养物中对红系集落形成(CFU-E)产生剂量相关的抑制作用。因此,有以下证据表明慢性肾衰竭患者血清中发现的体外红细胞生成抑制剂与多胺精胺相同:(a)抑制剂和放射性标记的精胺出现在相同的Bio-Gel P-2流出级分中;(b)当以尿毒症患者血清中报道的浓度向正常人血清中添加精胺,并在胎儿小鼠肝细胞培养物和正常人骨髓培养物中进行研究时,发现对红系集落(CFU-E)形成有剂量相关的抑制作用;(c)向精胺中加入特异性兔抗血清后,粗制尿毒症血清、尿毒症血清透析液以及来自Bio-Gel柱的尿毒症血清透析液级分对红系集落形成的抑制作用完全消除。